Autolus Therapeutics PLC (AUTL)
4.19
+0.08
(+1.95%)
USD |
NASDAQ |
May 03, 16:00
4.185
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Enterprise Value: 874.67M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 03, 2024 | 874.67M |
May 02, 2024 | 853.39M |
May 01, 2024 | 824.14M |
April 30, 2024 | 739.04M |
April 29, 2024 | 770.95M |
April 26, 2024 | 824.14M |
April 25, 2024 | 845.41M |
April 24, 2024 | 879.98M |
April 23, 2024 | 951.78M |
April 22, 2024 | 973.06M |
April 19, 2024 | 962.42M |
April 18, 2024 | 1.037B |
April 17, 2024 | 1.048B |
April 16, 2024 | 1.053B |
April 15, 2024 | 1.063B |
April 12, 2024 | 1.095B |
April 11, 2024 | 1.178B |
April 10, 2024 | 1.130B |
April 09, 2024 | 1.204B |
April 08, 2024 | 1.204B |
April 05, 2024 | 1.250B |
April 04, 2024 | 1.226B |
April 03, 2024 | 1.220B |
April 02, 2024 | 1.226B |
April 01, 2024 | 1.271B |
Date | Value |
---|---|
March 28, 2024 | 1.457B |
March 27, 2024 | 1.420B |
March 26, 2024 | 1.401B |
March 25, 2024 | 1.444B |
March 22, 2024 | 1.441B |
March 21, 2024 | 1.422B |
March 20, 2024 | 1.502B |
March 19, 2024 | 1.202B |
March 18, 2024 | 1.203B |
March 15, 2024 | 1.113B |
March 14, 2024 | 1.085B |
March 13, 2024 | 1.034B |
March 12, 2024 | 1.013B |
March 11, 2024 | 1.018B |
March 08, 2024 | 1.088B |
March 07, 2024 | 1.013B |
March 06, 2024 | 1.076B |
March 05, 2024 | 1.085B |
March 04, 2024 | 1.106B |
March 01, 2024 | 1.209B |
February 29, 2024 | 1.155B |
February 28, 2024 | 1.139B |
February 27, 2024 | 1.188B |
February 26, 2024 | 1.232B |
February 23, 2024 | 1.181B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-83.08M
Minimum
Jun 15 2022
1.502B
Maximum
Mar 20 2024
296.85M
Average
250.90M
Median
Enterprise Value Benchmarks
Adaptimmune Therapeutics PLC | 146.78M |
Biodexa Pharmaceuticals Plc | -2.432M |
NuCana PLC | -13.49M |
TC BioPharm (Holdings) PLC | 1.528M |
Mereo BioPharma Group PLC | 404.26M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -77.17M |
Total Expenses (Quarterly) | 40.89M |
EPS Diluted (Quarterly) | -0.45 |
Earnings Yield | -28.64% |
Normalized Earnings Yield | -22.78 |